Patent ID: 6387373
Filing Date: 2002-05-14
Classification: A61K,C12N

Abstract:
An adjuvanted influenza vaccine for producing an antigenic response to influenza, in vivo, in mammals, said vaccine comprising:an effective amount of an influenza antigen and an adjuvant, said adjuvant comprising oil-containing paucilamellar lipid vesicles having nonphospholipid materials as the primary wall forming constituent, wherein said paucilamellar lipid vesicles have 2-10 bilayers surrounding an amorphous central cavity, and wherein said nonphospholipid materials are selected from the group consisting of polyoxyethylene fatty acid esters, polyoxyethylene fatty acid ethers, polyoxyethylene sorbitan esters, polyoxyethylene glyceryl mono- and diesters, glyceryl mono- and distearate, sucrose distearate, propylene glycol stearate, long chain acyl hexosamides, long chain acyl amino acid amides, long chain acyl amides, glyceryl mono-and diesters, dimethyl acyl amines, C12-C20 fatty alcohols, C12-C20 glycol monoesters, and C12-C20 fatty acids, and wherein said vaccine increases the antigenic response when compared to the antigen alone or the antigen adjuvanted with alum, wherein the antigen is mixed in solution with the adjuvant.